A detailed history of Ikarian Capital, LLC transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 53,000 shares of BMEA stock, worth $212,530. This represents 0.09% of its overall portfolio holdings.

Number of Shares
53,000
Holding current value
$212,530
% of portfolio
0.09%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$21.66 - $41.8 $1.41 Million - $2.71 Million
64,900 Added 30.76%
275,875 $6.06 Million
Q1 2023

May 15, 2023

BUY
$6.8 - $32.35 $1.43 Million - $6.83 Million
210,975 New
210,975 $6.54 Million

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $117M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.